Method of treating B cell cancers by administering truncated BAFF receptors

US8821883B2 · kind B2 · utility

Assignee

• BIOGEN IDEC MA INC. · US

Inventors

• Christine Ambrose · Reading, US
• Jeffrey Thompson · Hightstown, US
• Yen-Ming Hsu · Lexington, US
• Dingyi Wen · Waltham, US
• Yaping Sun · Lexington, US

Key dates

• Filing date: Oct 4, 2012
• Grant date: Sep 2, 2014
• Expiry date: Oct 4, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.